Sonus Pharmaceuticals

www.oncogenex.com
Profile Unclaimed

Sonus Pharmaceuticals Reviews

0 Reviews
N/A
0 Reviews

Recommend to a friend
Approve of CEO
Sonus Pharmaceuticals President, CEO, and Director Scott Cormack
Scott Cormack
0 Ratings

Sonus Pharmaceuticals Interviews

Interview Experience

Interview Experience

0%
100%
0%

Getting an Interview

Getting an Interview

100%

Interview Difficulty

1.0
Average

Interview Difficulty

Hard

Average

Easy
  1.  

    Driver Interview

    Anonymous Employee
    Anonymous Employee
    Application Details

    I applied online. The process took a dayinterviewed at Sonus Pharmaceuticals in December 2008.

    Interview Details

    Panel interview with Two and one driving test in a test circuit

    Interview Questions
    Declined Offer
    Neutral Experience
    Easy Interview

Sonus Pharmaceuticals Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Website www.oncogenex.com
Headquarters Bothell, WA
Size 16 to 50 Employees
Founded Unknown
Type Company - Public (OGXI)
Industry Biotech & Pharmaceuticals
Revenue $25 to $50 million (USD) per year

OncoGenex Pharmaceuticals (formerly Sonus Pharmaceuticals) is on the hunt for new and better cancer therapies. With its 2008 merger with OncoGenex Technologies, the company took on a new name and an expanded pipeline of investigational oncology drugs. The merger contributed several candidates (including OGX-011, OGX-427, and OGX-225) that fight treatment-resistant tumors. Another candidate, SN2310, is a version of a proven class of oncology drugs called camptothecins. The company previously halted development on another investigational drug, a version of common cancer drug... More

Work at Sonus Pharmaceuticals? Share Your Experiences

Sonus Pharmaceuticals

 
Click to Rate
or